Ads
related to: breast cancer, drugmaker
Search results
Seagen's breast cancer therapy succeeds in late-stage study
Reuters via AOL· 10 months agoPfizer in March agreed to acquire Seagen and its targeted therapies in a $43 billion deal to help...
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
Reuters via Yahoo Finance· 1 year agoNovartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial...
AstraZeneca and Daiichi's breast cancer drug meets goal in study
Reuters via Yahoo News· 9 months agoBy Maggie Fick (Reuters) -AstraZeneca said on Friday its experimental precision drug had slowed the...
US FDA approves AstraZeneca's breast cancer drug combination
Reuters via Yahoo News· 7 months agoThe FDA decision allows use of the drug, chemically known as capivasertib, in combination with the...
Lung cancer deaths cut in half with AstraZeneca pill, large trial finds
NBC News via Yahoo News· 1 year agoA once-daily pill from drugmaker AstraZeneca cut deaths in half among a subset of early-stage lung...
Novartis buoyed by trial success in early-stage breast cancer
Reuters via Yahoo News· 1 year agoFRANKFURT (Reuters) -Novartis's Kisqali breast cancer drug cut the risk of recurrence in women who...
New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy
Verywell Health via Yahoo News· 1 month agoIllustration by Julie Bang for Verywell Health Fact checked by Nick Blackmer Key Takeaways The FDA...
Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio
Zacks via Yahoo Finance· 1 year agoPfizer PFE has offered to buy cancer drugmaker, Seagen SGEN for $229 per share in cash, which adds...
AstraZeneca experimental drug meets main goals of breast cancer study
Reuters via Yahoo News· 2 years ago(Reuters) - AstraZeneca Plc said on Wednesday its experimental drug capivasertib was able to help...
Novartis, helped by cost cuts, raises full-year outlook
Reuters via Yahoo Finance· 1 year agoFRANKFURT (Reuters) -Novartis on Tuesday raised its full-year earnings outlook following cost cuts,...
